First sale of the OncoSil™ breakthrough† device

2020 achievements – first sale of the OncoSil^TM System in New Zealand

OncoSil Medical is proud to announce achievement of its first sale which occurred in New Zealand in October 2020. The first sale represents an important milestone for OncoSil Medical as we begin transforming ourselves into a global commercial-stage medical device company.

OncoSil™ received approvals in Europe, UK, Switzerland, Singapore, and Malaysia

2020 achievements – approvals in Europe, UK, Switzerland, Singapore, and Malaysia

The OncoSil^TM System received CE Marking approval from the British Standards Institute (BSI) in April 2020.¹ This milestone was followed by approvals in Singapore, Malaysia and Switzerland.

REFERENCES 1. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.

2020 achievements – Breakthrough Device Designation by BSI

In April 2020, the British Standards Institute (BSI) designated the OncoSil^TM device as a breakthrough product as per MEDDEV guidance¹.

REFERENCES 1. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.

2020 achievements – Breakthrough Device Designation by FDA

In March 2020, the FDA granted Breakthrough Device Designation for the OncoSil^TM System.

2020 achievements – participation in 4 major medical congresses

In 2020, OncoSil Medical had the opportunity to sponsor and virtually attend several major medical education events: the London Pancreas Workshop and the Pancreatic Cancer UK Annual Summit in September, the New-Zealand Society for Oncology Conference in October and the World Congress of the International Hepato-Pancreato-Biliary Association in November.

2020 achievements – the OncoSil Medical team has doubled in size

To support its growth plans, OncoSil Medical welcomed 10 new team members across Germany, Italy, the UK, Benelux and Australia. They joined the sales, marketing, regulatory affairs and quality, manufacturing and operations departments.

WB00-AU-0820